Treatment Options for Advanced Melanoma From 5 Experts: An Online Tool

Michael Postow, MD
Program Director
Michael Atkins Headshot
Michael B. Atkins, MD
Adil Daud, MD
person default
Kim Margolin, MD
person default
Hussein Tawbi, MD
Released: May 3, 2019
Back Next

References

  1. Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018;19:181-193.
  2. American Joint Committee on Cancer. Cancer Staging Manual, 8th Edition. Chicago, IL: Springer; 2018.
  3. Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. Int J Cancer. 2014;134:2961-2971.
  4. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789-1801.
  5. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375:1845-1855.
  6. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472-492.
  7. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234-240.
  8. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-1246.
  9. Long GV, Grob JJ, Nathan P, et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016;17:1743-1754.
  10. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368-376.
  11. Neuman HB, Patel A, Ishill N, et al. A single-institution validation of the AJCC staging system for stage IV melanoma. Ann Surg Oncol. 2008;15:2034-2041.
  12. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-168.
  13. Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014;15:954-965.
  14. Talimogene laherparepvec [package insert]. Thousand Oaks, CA: BioVex, Inc, a subsidiary of Amgen Inc; 2017.
Back Next

Disclaimer

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Treatment Options From 5 Experts for Advanced Melanoma: An Online Tool,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

The “Treatment Options From 5 Experts for Advanced Melanoma: An Online Tool” Interactive Decision Support Tool is designed to educate patients on optimal management decisions for advanced melanoma based on their specific cancer characteristics. The information provided is based on the expert guidance of 5 melanoma experts: Michael B. Atkins, MD; Adil Daud, MD; Kim Margolin, MD; Michael Postow, MD; and Hussein Tawbi, MD.

Although the information contained in the “Treatment Options From 5 Experts for Advanced Melanoma: An Online Tool” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. Patients should always discuss their healthcare decisions with their oncology care team. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all data on the Clinical Care Options Web site including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2019 Clinical Care Options, LLC. All rights reserved.

Provided by Postgraduate Institute for Medicine
PIM Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Grace Logo
This activity is supported by educational grants from
Merck & Co., Inc.
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings